This research article focuses on the development of a novel glycan-specific lectin-based immunoassay for the detection of Prostate Specific Antigen (PSA), a crucial biomarker used in the diagnosis and monitoring of prostate cancer. The study highlights the importance of analyzing glycosylation patterns of PSA to differentiate between normal and cancer-associated forms.

The developed assay utilizes a newly characterized anti-PSA monoclonal antibody along with lectin-based detection to identify specific glycan linkages such as fucosylation and sialylation. The findings demonstrate that this method can effectively detect altered glycosylation patterns in PSA associated with prostate cancer, offering improved specificity compared to conventional PSA assays.

Overall, the assay provides a sensitive, reliable, and cost-effective approach for early detection and better differentiation of prostate cancer, making it a promising tool for clinical diagnostics and screening.